Shorter and Safer Treatment Regimens for Latent TB

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

June 1, 2029

Conditions
Tuberculosis Infection, Latent
Interventions
DRUG

rifampin standard arm

120 doses daily self-administered rifampin at 10mg/kg/day (max 600mg/day)

DRUG

rifampin double dose

60 doses daily self-administered rifampin at 20 mg/kg (max. 1200 mg/day)

DRUG

levofloxacin and rifapentine

30 doses daily self-administered levofloxacin (15 mg/kg, max 750mg/day and rifapentine (10mg/kg, max: 600mg)

Trial Locations (13)

Unknown

Centre National Hospitalier Universitaire de Pneumo Phtisiologie de Cotonou (CNHU-PPC), Cotonou

Manaus, Manaus

Unviversity of Calgary, Calgary

BCCDC TB clinic, Vancouver

University of Manitoba, Winnipeg

University of Ottawa, Ottawa

Universitas Padjadjaran, Klinik Penelitian Tuberculosis (TB research clinic), Bandung

Vietnam, Ho Chi Minh City

T6G 2C8

The Governors of the University of Alberta, Edmonton

M5B1W8

St. Michael's Hospital, Toronto

M6M2J5

University Health Network, Toronto

H4A 3J1

MUHC, Montreal

H4J 1C5

Hopital du Sacré-Coeur de Montreal, Montreal

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT06498414 - Shorter and Safer Treatment Regimens for Latent TB | Biotech Hunter | Biotech Hunter